Cargando…
Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
Receptors on T and NK cells systematically propagate highly complex signaling cascades that direct immune effector functions, leading to protective immunity. While extensive studies have delineated hundreds of signaling events that take place upon receptor engagement, the precise molecular mechanism...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863891/ https://www.ncbi.nlm.nih.gov/pubmed/27242783 http://dx.doi.org/10.3389/fimmu.2016.00176 |
_version_ | 1782431556838621184 |
---|---|
author | Rajasekaran, Kamalakannan Riese, Matthew J. Rao, Sridhar Wang, Li Thakar, Monica S. Sentman, Charles L. Malarkannan, Subramaniam |
author_facet | Rajasekaran, Kamalakannan Riese, Matthew J. Rao, Sridhar Wang, Li Thakar, Monica S. Sentman, Charles L. Malarkannan, Subramaniam |
author_sort | Rajasekaran, Kamalakannan |
collection | PubMed |
description | Receptors on T and NK cells systematically propagate highly complex signaling cascades that direct immune effector functions, leading to protective immunity. While extensive studies have delineated hundreds of signaling events that take place upon receptor engagement, the precise molecular mechanism that differentially regulates the induction or repression of a unique effector function is yet to be fully defined. Such knowledge can potentiate the tailoring of signal transductions and transform cancer immunotherapies. Targeted manipulations of signaling cascades can augment one effector function such as antitumor cytotoxicity while contain the overt generation of pro-inflammatory cytokines that contribute to treatment-related toxicity such as “cytokine storm” and “cytokine-release syndrome” or lead to autoimmune diseases. Here, we summarize how individual signaling molecules or nodes may be optimally targeted to permit selective ablation of toxic immune side effects. |
format | Online Article Text |
id | pubmed-4863891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48638912016-05-30 Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy Rajasekaran, Kamalakannan Riese, Matthew J. Rao, Sridhar Wang, Li Thakar, Monica S. Sentman, Charles L. Malarkannan, Subramaniam Front Immunol Immunology Receptors on T and NK cells systematically propagate highly complex signaling cascades that direct immune effector functions, leading to protective immunity. While extensive studies have delineated hundreds of signaling events that take place upon receptor engagement, the precise molecular mechanism that differentially regulates the induction or repression of a unique effector function is yet to be fully defined. Such knowledge can potentiate the tailoring of signal transductions and transform cancer immunotherapies. Targeted manipulations of signaling cascades can augment one effector function such as antitumor cytotoxicity while contain the overt generation of pro-inflammatory cytokines that contribute to treatment-related toxicity such as “cytokine storm” and “cytokine-release syndrome” or lead to autoimmune diseases. Here, we summarize how individual signaling molecules or nodes may be optimally targeted to permit selective ablation of toxic immune side effects. Frontiers Media S.A. 2016-05-12 /pmc/articles/PMC4863891/ /pubmed/27242783 http://dx.doi.org/10.3389/fimmu.2016.00176 Text en Copyright © 2016 Rajasekaran, Riese, Rao, Wang, Thakar, Sentman and Malarkannan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Rajasekaran, Kamalakannan Riese, Matthew J. Rao, Sridhar Wang, Li Thakar, Monica S. Sentman, Charles L. Malarkannan, Subramaniam Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy |
title | Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy |
title_full | Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy |
title_fullStr | Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy |
title_full_unstemmed | Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy |
title_short | Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy |
title_sort | signaling in effector lymphocytes: insights toward safer immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863891/ https://www.ncbi.nlm.nih.gov/pubmed/27242783 http://dx.doi.org/10.3389/fimmu.2016.00176 |
work_keys_str_mv | AT rajasekarankamalakannan signalingineffectorlymphocytesinsightstowardsaferimmunotherapy AT riesematthewj signalingineffectorlymphocytesinsightstowardsaferimmunotherapy AT raosridhar signalingineffectorlymphocytesinsightstowardsaferimmunotherapy AT wangli signalingineffectorlymphocytesinsightstowardsaferimmunotherapy AT thakarmonicas signalingineffectorlymphocytesinsightstowardsaferimmunotherapy AT sentmancharlesl signalingineffectorlymphocytesinsightstowardsaferimmunotherapy AT malarkannansubramaniam signalingineffectorlymphocytesinsightstowardsaferimmunotherapy |